Welcome to our dedicated page for Guardant Health SEC filings (Ticker: GH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. Chief People Officer Terilyn J. Monroe reported routine equity compensation activity. On July 1, 2026, restricted stock units converted into a total of 4,020 shares of Common Stock, reflecting scheduled vesting of prior awards. The company retained 2,099 shares at $170.77 per share to cover Ms. Monroe’s tax withholding obligations, rather than through an open-market sale. Following these transactions, she continues to hold both common shares and unvested restricted stock units as part of her compensation.
Guardant Health, Inc. Chief Information Officer Kumud Kalia reported routine equity compensation activity. On 2026-07-01, several batches of restricted stock units vested and were converted into a total of 6,046 shares of common stock at a conversion price of $0.00 per share.
To cover associated tax obligations from this vesting, 3,066 shares of common stock were withheld by the company at a value of $170.77 per share, as described in the footnotes. These transactions reflect compensation-related vesting and tax withholding rather than open-market buying or selling.
Guardant Health, Inc. Chief Commercial Officer Chris Freeman reported compensation-related equity activity involving restricted stock units. On July 1, 2026, RSU awards vested and were converted into a total of 7,414 shares of common stock, reflecting derivative exercises rather than open-market purchases.
To cover tax obligations arising from this vesting, 3,141 shares of common stock were retained by the company at a value of $170.77 per share, as noted in the footnotes. The transactions do not include any open-market buying or selling, and are characterized as routine equity compensation and tax withholding events.
Guardant Health Chief Technology Officer Darya Chudova reported routine equity compensation activity involving restricted stock units and related tax withholding. On July 1, 2026, several restricted stock unit awards converted into common stock, reflected as multiple exercise transactions.
In connection with the vesting, 4,318 shares of common stock were retained by Guardant Health at $170.77 per share to cover her tax withholding obligations, as described in the footnotes. Following these transactions, Chudova directly held 78,373 shares of Guardant Health common stock.
Guardant Health, Inc.’s Chief Financial Officer Michael Brian Bell reported routine equity compensation activity involving restricted stock units that vested into common stock. On July 1, 2026, RSU conversions delivered 7,278 shares of common stock, while 3,914 shares were withheld at $170.77 per share to cover tax obligations, rather than sold in the open market.
Guardant Health, Inc. director and Co-Chief Executive Officer Helmy Eltoukhy, through the Helmy A. Eltoukhy Revocable Trust, reported routine equity compensation activity involving restricted stock units and related tax withholding.
On June 30 and July 1, 2026, a total of 36,529 restricted stock units were converted into an equal number of shares of common stock at a conversion price of $0.00 per share. To satisfy tax withholding obligations tied to these vestings, 18,514 shares of common stock were retained by the company at prices of $150.03 and $170.77 per share, as noted in the footnotes. These F-code dispositions reflect payment of tax liabilities rather than open-market sales.
Guardant Health, Inc. Co-Chief Executive Officer AmirAli Talasaz reported routine equity compensation activity involving restricted stock units. On June 30 and July 1, 2026, a total of 36,529 restricted stock units converted into common stock through derivative exercises, reflecting scheduled vesting.
Across the same dates, 18,514 common shares were withheld and retained by the company at prices of $150.03 and $170.77 per share to cover tax liabilities associated with these vesting events. The transactions occurred through the Talasaz and Eskandari 2017 Family Trust and do not involve any open-market purchases or sales.
Guardant Health director Steve E. Krognes reported an exercise of restricted stock units that delivered 155 shares of common stock on June 30, 2026. These RSUs were from an award granted on August 9, 2022, which vested 25% on June 30, 2023 and the remaining 75% over the following three years.
After this derivative exercise, Krognes directly holds 14,580 shares of Guardant Health common stock. This Form 4 reflects a compensation-related vesting and conversion of equity awards, with no open-market buying or selling reported in this filing.
Guardant Health filed a Form 144 reporting proposed resale of 4,000 shares of Common Stock via a cashless employee option exercise on 07/01/2026. The filing also lists recent open-market sales by Meghan V. Joyce totaling 20,203 shares across June 2026 with proceeds shown per trade.
Guardant Health Chief Information Officer Kumud Kalia reported small, offsetting insider trades in company common stock. On June 10 and June 15, Kalia executed open-market sales totaling 1,200 shares at prices around $130–$131 per share and an open-market purchase of 600 shares at about $130.76 per share.
After these transactions, Kalia directly holds 40,814 shares of Guardant Health common stock. A footnote states that, based on these trades, the company identified recoverable Section 16(b) short-swing profits of $192, which Kalia has paid back to the company.